AZN's Repurposed COVID-19 Drug Fails, NAVB On Watch, CVAC Rallies On Storage Advantage Of CVnCoV

Today's Daily Dose brings you news about the failure of AstraZeneca's repurposed COVID-19 drug, reverse merger of MyMD with Akers, storage advantage of CureVac's COVID-19 shot, Navidea's promising results from its NAV3-31 phase IIb study, Inhibrx' phase I trial results of INBRX-109 in bone cancer.

from RTT - Biotech https://ift.tt/2IsuMl3
via IFTTT